Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · PULSE BIOSCIENCES, INC. (PLSE)

Pulse Biosciences Partners with Clayman Thyroid Center in Tampa for Vybrance Use

Neutral Impact 2 of 5 product/contract Written later

Pulse Biosciences announced on October 14, 2026, a commercial and clinical partnership with the Clayman Thyroid Center at the Hospital for Endocrine Surgery in Tampa, Florida, and its affiliates. The center is now treating patients with the nPulse Vybrance Percutaneous Electrode System, and the two parties will collect real-world outcomes data and work on formal clinical studies of the system for benign thyroid nodules. The filing does not disclose financial terms, so the partnership's effect on Pulse Biosciences' revenue is not quantified.

Key points

  • Partnership announced October 14, 2026, with the Clayman Thyroid Center and its affiliates in Tampa, Florida
  • The center is now treating patients with the Vybrance System as part of the company's controlled market development strategy
  • The center is the only site in the Tampa Bay Area offering nPulse technology for symptomatic benign thyroid nodules
  • Collaboration covers real-world outcomes collection and formal clinical studies; the filing gives no financial terms

The filing

CompanyPULSE BIOSCIENCES, INC. (PLSE)
Form8-K, current report
Filed with the SECOct 14, 2026, 8:43 AM ET
Accession number0001437749-26-032601

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 14, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.